a. In vitro experiments demonstrated that Dual-RevCAR T cells exhibited full activation exclusively in the concurrent presence of both CEA and EpCAM RevTMs, leading to specific killing of CEA+EpCAM + CRC cells along with concomitant cytokine release.b. In vivo experiments utilizing a mouse tumour xenograft model revealed that Dual-RevCAR T cells effectively suppressed tumour growth only upon simultaneous administration of both CEA and EpCAM RevTMs. The gene discussed is CEACAM5; the disease is colorectal carcinoma.